According to scientists, in a study of suggesting ways to reduce doses when stocks are small, people who have stabilized from the novel coronavirus infection might want only one shot. This is in opposition to the prescribed two shots. It is only applicable if they are getting the Moderna or Pfizer COVID-19 vaccines.
Posted in the preprint repository medRxiv, the yet-to-be peer-reviewed report examined the antibody responses in 109 individuals with and without recorded pre-existing resistance to the novel coronavirus.
“For individuals with pre-existing immunity to SARS-CoV-2 the first vaccine dose likely immunologically resembles the booster dose in naive individuals,” the scientists wrote in the study.
What More Scientists Wants To Say:
According to scientists, including Florian Krammer of the Icahn School of Medicine in the US, a single dose of mRNA vaccine induces very fast immune responses from prior exposure in individuals still possessing coronavirus antibodies.
In the analysis, the researchers studied mRNA vaccines that use fragments of the viral genetic material in making coronavirus spike proteins possible for human cells.
These proteins prepare vaccine recipients’ immune systems to combat the real infectious coronavirus when the virus is encountered by their body.
The scientists suggested that in recovered COVID-19 patients, the post-vaccine antibody levels are equivalent to or surpass the levels seen in people without previous virus exposure who received two vaccinations.
Another peer-reviewed research in medRxiv also examined antibody responses in healthcare workers who had previously recovered from the virus from a single dose of Pfizer-BioNTech or Moderna vaccines.
“Although we did not have peak titers for these individuals after natural infection, the titers developed after single vaccination was higher than peak titers in inpatients and outpatients with COVID-19, similar to what has been described in primary vaccination after two doses of the spike-based mRNA vaccines,” the researchers wrote in the study.
The secondary reaction happens by activation of the memory B cells of the immune system.This is according to scientists from the University of Maryland School of Medicine in the US.
The scientists suggest a single-dose vaccine approach for patients who have already had laboratory-confirmed COVID-19, centered on the results
Lawrence Young, a virologist and professor of molecular oncology at the University of Warwick in the United Kingdom, believes that more research will solve this problem.
“…we should be doing further studies which look at giving previously infected individuals one dose of an mRNA vaccine,” said Young, who was also unrelated to the two studies.
“If future work can confirm this high level of immunity post a single mRNA vaccine in this group of individuals, this could become a viable option when there are concerns around vaccine supply,” he added in a statement.